HeberFERON as a therapeutic option for the treatment of advance a | 11362
Journal of Clinical & Experimental Dermatology Research

Journal of Clinical & Experimental Dermatology Research
Open Access

ISSN: 2155-9554

+44 1478 350008

HeberFERON as a therapeutic option for the treatment of advance and high risk basal cell carcinomas

17th European Dermatology Congress

March 01-03, 2018 | Paris, France

Iraldo Bello Rivero

Center for Genetic Engineering and Biotechnology, Cuba

Scientific Tracks Abstracts: J Clin Exp Dermatol Res

Abstract :

Statement of the Problem: The incidence of basal cell carcinoma is increasing over the world and is one of the most-costly tumors, however, has lower rate of mortality. These tumors promote high rates of morbidity in face cosmetic locations. IFNs are proteins with anti-tumor properties that have been used in the treatment of non-melanoma skin tumors in an effective and safe way. HeberFERON formulation combines IFNs alpha2b and gamma. HeberFERON was used in several clinical trials in patients with non-melanoma skin tumors. Methodology & Theoretical Orientation: The administration of the IFNs was performed perilesionally using doses from 3.5 to 10.5 MUI, 3 times a week for 3 weeks. PK/PD studies were conducted. All the patients included in the studies gave their consent for participation and the studies were approved by the ethics committees of the participating institutions and CECMED. Findings: Clinical studies of HeberFERON revealed that this formulation generated a faster anti-tumor response than the IFNs separately, as well as a greater number of complete responses, which agrees with the results of the PK/PD that demonstrated a superior biological potency of HeberFERON. The follow-up studies of patients with BCC or SCCS who obtained complete responses (CR) showed that these remain at 5 years free of tumor and that the rate of appearance of new lesions decreased by 8 times. The aesthetic results of these treatments are very favorable and the use of the product is safe. A global analysis of 245 patients with BCC treated with HeberFERON shows a disease control of 98.6% with 61.9% CR and 88.4% objective response. BCC patients received intramuscular treatment with HeberFERON with encouraging results and improved quality of life. Conclusion & Significance: HeberFERON is a new formulation of IFNs with curative capacity for non-melanoma skin tumors, with very favorable aesthetic results, safe and easy to use.

Biography :

Iraldo Bello Rivero has completed his Masters in Chemistry at I.I.Mechnikov National University, Odessa, Ukraine and PhD from Havana University. He carried out Fellowships with Dr. Michel Aguet (1988) at Institute of Immunology and Virology, Zurich, Switzerland; with Dr. Erik Lundgren (1994) at Department of Molecular Biology, Umea University, Sweden and with Dr. Marco Soria (1995) at Department of Biological and Technological Research, San-Raffaele Scientific Institute, Italy. He was the Head of Clinical Trial Laboratory at CIGB (1994-2005). He has published more than 30 papers in reputed journals and received Cuban Academy of Sciences Awards (1990, 2006) and Public Health National Award (Cuba) in 2010 and 2016.